CI
SPRY icon

CAZ Investments’s ARS Pharmaceuticals SPRY Stock Holding History

CAZ Investments’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.1K Hold
2,000
– – 0.02% 38
2025
Q4 		$23.3K Hold
2,000
– – 0.04% 26
2025
Q3 		$20.1K Hold
2,000
– – 0.04% 27
2025
Q2 		$34.9K Sell
2,000
-500
-20% -$7.21K 0.2% 20
2025
Q1 		$31K Hold
2,500
– – 0.22% 21
2024
Q4 		$26K Hold
2,500
– – 0.04% 29
2024
Q3 		$36K Sell
2,500
-7,500
-75% -$89.2K 0.02% 28
2024
Q2 		$85K Buy
+10,000
New +$88.7K 0.03% 23

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CAZ Investments's SPRY Position: Q1 2026 in Review

CAZ Investments held its ARS Pharmaceuticals (SPRY) position steady in Q1 2026 at 2,000 shares worth $16.1K. The position accounts for 0.02% of the portfolio, ranked #38.

CAZ Investments first reported a position in SPRY in Q2 2024 and has held it in 8 quarters since. The position peaked at $85K in Q2 2024. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • CAZ Investments held 2,000 shares of ARS Pharmaceuticals worth $16.1K as of Q1 2026.
  • CAZ Investments left its ARS Pharmaceuticals share count unchanged in Q1 2026.
  • ARS Pharmaceuticals made up 0.02% of CAZ Investments's portfolio in Q1 2026, its #38 holding.
  • CAZ Investments first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • CAZ Investments's ARS Pharmaceuticals position peaked at $85K in Q2 2024.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on CAZ Investments's 13F filing for Q1 2026, filed 12 May 2026.